Last Updated:
Create account to add to watchlist!
Create account to add to watchlist!

BioPlus Acquisition Corp. - BIOS

  • Commons



    BIOS Vol: 1.9K

  • Warrants



    BIOSW Vol: 114.0

  • Units



    BIOSU Vol: 0.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 248.8M
Average Volume: 196.3K
52W Range: $9.91 - $11.24
Weekly %: -0.28%
Monthly %: +0.48%
Inst Owners: 0


Target: Searching
Days Since IPO: 566
Unit composition:
Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-third of one redeemable warrant
Trust Size: 22000000.0M

🕵Stocktwit Mentions

MaryLamote1 posted at 2023-06-20T16:08:19Z


tickeron posted at 2023-06-18T14:29:47Z

What are the most profitable stocks right now? Pick the best $BIOS vs. $ISO vs. $SAFE. #BioPlusAcquisition

Quantisnow posted at 2023-06-14T10:32:13Z

$BIOS 📜 SEC Form 425 filed by BioPlus Acquisition Corp. 45 seconds delayed.

EarningsInsider posted at 2023-06-14T10:29:52Z

BioPlus Acquisition Corp. Files SEC Form 8-K $BIOS

Quantisnow posted at 2023-06-14T10:07:09Z

$BIOS 📜 BioPlus Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits 45 seconds delayed.

Quantisnow posted at 2023-06-13T12:55:08Z

$BIOS 📰 Avertix's Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando 45 seconds delayed.

cctranscripts posted at 2023-06-13T10:11:57Z

Alex Vieux just provided an update on activist position in BioScrip $BIOS

Quantisnow posted at 2023-06-13T10:03:40Z

$BIOS 📜 SEC Form SC 13D/A filed by BioPlus Acquisition Corp. (Amendment) 45 seconds delayed.

cctranscripts posted at 2023-06-13T01:19:27Z

Major owner of BioScrip just picked up 5,749,999 shares $BIOS

Quantisnow posted at 2023-06-13T01:18:56Z

$BIOS 📜 SEC Form 4 filed by Bioplus Sponsor Llc 45 seconds delayed.

Trade_Hub posted at 2023-06-09T13:38:57Z

🚨 Update 🚨 $BIOS Hit PT! Posted by @AlertsWolf Delay: 5 min

Trade_Hub posted at 2023-06-09T13:37:20Z

🚨 New Trade 🚨 👀 Ticker: $BIOS 🎯 Entry: $11.77 Break 💰 PT: $11.90/$12.00+ ❌ SL: 3% below entry! 📝 Comments: Day Trade Posted by @AlertsWolf Delay: 5 min

cctranscripts posted at 2023-06-08T20:39:45Z

Entry into a Material Definitive $BIOS

Quantisnow posted at 2023-06-08T20:19:07Z

$BIOS 📜 BioPlus Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits 45 seconds delayed.

Trade_Hub posted at 2023-06-08T13:41:10Z

🚨 Update 🚨 $BIOS disregard alert I mean $12.70 not $13.70 Posted by @AlertsWolf Delay: 5 min

smalltraderjoe posted at 2023-06-02T22:25:13Z

$SDA Another Chinese company $SFWLand no one knows what is their financials or what exactly they do in China, I am taking a short position. If anyone is interested please feel free to join the party . $TOP $UCAR $BIOS

cctranscripts posted at 2023-05-30T20:34:50Z

BioScrip just filed its Current report, items 7.01 and 9.01 $BIOS

cctranscripts posted at 2023-05-30T20:32:36Z

BioScrip just filed its Prospectuses and communications, busines $BIOS

Quantisnow posted at 2023-05-30T20:03:55Z

$BIOS 📜 BioPlus Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits 45 seconds delayed.

dividendinvestorbyeagle posted at 2023-05-24T13:13:48Z

$BIOS hit 52 week high (Cl A/BioPlus Acquisition Corp)

ChartMill posted at 2023-05-24T09:03:00Z

$BIOS is currently making a new 52 week high. This is a strong signal.

dividendinvestorbyeagle posted at 2023-05-23T12:04:21Z

$BIOS hit 52 week high (Cl A/BioPlus Acquisition Corp)

cctranscripts posted at 2023-05-19T21:10:49Z

Prospectuses and communications, business combinations $BIOS

Quantisnow posted at 2023-05-19T20:51:21Z

$BIOS 📜 SEC Form 425 filed by BioPlus Acquisition Corp. 45 seconds delayed.

cctranscripts posted at 2023-05-19T20:10:26Z

Prospectuses and communications, business combinations $BIOS

Quantisnow posted at 2023-05-19T20:06:27Z

$BIOS 📜 SEC Form 425 filed by BioPlus Acquisition Corp. Get the next market-moving insight 45 seconds early at ➡️ ⬅️

shortvolumes posted at 2023-05-19T15:41:28Z

Short sale volume (not short interest) for $BIOS at 2023-05-18 is 98%. via @shortvolumes

dividendinvestorbyeagle posted at 2023-05-18T12:30:27Z

$BIOS hit 52 week high (Cl A/BioPlus Acquisition Corp)

dividendinvestorbyeagle posted at 2023-05-16T12:00:20Z

$BIOS hit 52 week high (Cl A/BioPlus Acquisition Corp)

Quantisnow posted at 2023-05-15T20:21:16Z

$BIOS 📜 SEC Form 10-Q filed by BioPlus Acquisition Corp. 45 seconds delayed.


Our officers, directors and director nominees are as follows: Name Age Position Alan C. Mendelson 73 Chairman Ross Haghighat 57 Co-Chief Executive Officer and Chief Financial Officer J. Leighton Read, M.D. 70 Co-Chief Executive Officer Louis G. Lange, M.D., Ph.D. 72 Director nominee Stephen Sherwin, M.D. 72 Director nominee Jonathan Rigby 53 Director nominee Glen Giovannetti 58 Director nominee Alan C. Mendelson, our Chairman, is a Retired Partner of Latham & Watkins LLP (“Latham”), where he spearheaded the growth of the partnership’s life sciences practice. Mr. Mendelson is widely recognized as a leading figure in the biotechnology ecosystem, having practiced law in the biotechnology industry since 1980. Mr. Mendelson started his career with Cooley LLP, where he was an associate and partner from 1973 through May 2000, when he joined Latham. At Latham, Mr. Mendelson served as the Global Co-Chair of the Life Sciences Industry Group. As of January 2021, The Legal 500, an industry publishing firm, ranked Mr. Mendelson among just four individuals receiving a star in its Hall of Fame for legal professionals serving the life sciences sector. In addition, Mr. Mendelson was recognized as one of the 100 most influential lawyers in the United States by the National Law Journal in 1994, 1997, 2000 and 2006. Mr. Mendelson retired from Latham in December 2020. Mr. Mendelson served as the incorporator of Amgen Inc. (NASDAQ: AMGN) in April 1980 and played a leading role in all of the major transactions in which Amgen engaged during the first 10 years of its existence, including its sole round of venture capital financing, its IPO, a joint venture with Kirin Brewery, major research and development partnerships, a European convertible debt transaction and a co-promotion agreement for Europe with Roche. From April 1990 to April 1991, Mr. Mendelson served as secretary and acting general counsel of Amgen. Mr. Mendelson brings extensive public company board and leadership experience in the life sciences sector. Mr. Mendelson currently serves as the corporate secretary and part-time general counsel of Blade Therapeutics, Inc., and on the Board of Directors at Coherus Biosciences (NASDAQ: CHRS) and several private companies, including TriSalus Life Sciences, Inc., BBI Medical Solutions LLC, Neuvogen, Inc., and Xomics Biopharma, Inc. He previously served on the Board of Directors at several public biotechnology companies, including Aviron Inc. (NASDAQ: AVIR), CV Therapeutics, Inc. (NASDAQ: CVTX), QLT, Inc. (NASDAQ: QLTI), and Valentis, Inc (NASDAQ: VLTS). Mr. Mendelson has also served as corporate secretary of Intuitive Surgical (NASDAQ: ISRG), Corvus Pharmaceuticals (NASDAQ: CRVS), Eargo, Inc. (NASDAQ: EAR) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). He also serves on the boards of trustees of the UC Berkeley Foundation and The Buck Institute for Research on Aging and on the board of directors of the National Kidney Foundation. Mr. Mendelson received a B.A. in Political Science from the University of California, Berkeley and a J.D. from Harvard Law School. We believe that Mr. Mendelson is qualified to serve as our Chairman due to his extensive outside counsel and board experience in the life sciences industry. Ross Haghighat, one of our co-Chief Executive Officers and Chief Financial Officer, is a United States based business executive, serial entrepreneur, and venture capitalist. Mr. Haghighat is the founding partner at Jasper Capital Partners, an investment firm investing in transformational technology-inspired growth companies focused on Australia and Asia, and Chairman of Triton Systems, Inc, a private early to mid-stage product 130 Table of Contents development and venture firm creating product-driven enterprises focusing on next-generation innovative technologies including microsensors, medical devices, immunotherapy. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led Coretek Inc, a photonic-based firm that developed the first tunable optoelectronic laser platform for telecom and was acquired by Nortel Networks in 2001 for $1.4 billion. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics (NASDAQ: KDNY), a leading immunotherapy company targeting autoimmune, inflammatory renal and oncology diseases, where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp. (NASDAQ: CCAC), a blank check company focused on consummating a deal within the clean technology industry in China or Asia; Mr. Haghighat serves as Chair of the Audit Committee, Fluence Corporation (ASX: FLC), a leading EGS global water treatment technology company, where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems, a commercial stage private medical device company with a pipeline of implantable cardiovascular devices with product distribution in US, Australia and Asia, where Mr. Haghighat serves as Lead Director and FRX Polymers, Inc., a global sustainable specialty chemicals company, where Mr. Haghighat serves as Chairman. These roles position Mr. Haghighat to help identify next generation trends, and equip him with the network and access to identify and select attractive targets that meet our acquisition criteria. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. We believe that Mr. Haghighat is qualified to serve as our co-Chief Executive Officer and Chief Financial Officer due to his extensive operational, financial management and board experience in the life sciences industry. J. Leighton Read, M.D., one of our co-Chief Executive Officers and a Director nominee, has over three decades of experience as a C-level and Board-level executive at leading health science firms. In addition to steering these firms toward commercial success at scale, Dr. Read has successfully engineered multiple exits to industry-leading strategic buyers. From 2003 to 2005, Dr. Read served as founding Chief Executive Officer at Avidia, a biopharmaceutical company engaged in discovering and developing therapeutic proteins and continued on the board representing Alloy Ventures through its acquisition by Amgen (NASDAQ: AMGN) in September 2006. Prior to Avidia, Dr. Read served as the Founder, Chairman and Chief Executive Officer of Aviron (NASDAQ: AVIR), the vaccine developer that created FluMist, leading the company through its initial public offering in November 1996 and continuing as Chairman and Director until its sale to MedImmune (NASDAQ: MEDI) in December 2001 for $1.5 billion. From 1988 to 1991, Dr. Read was Co-Founder and Managing Director of Affymax NV (NASDAQ: AFMXF), a research-stage biopharmaceutical company developing peptide-based drugs, which was later acquired by Glaxo in 1995 for $533 million. Dr. Read also brings extensive board leadership experience, and currently serves on the Board of Directors of several biotechnology companies including Global Kinetics Corporation, a digital health company focused on the management of Parkinson’s disease, where Dr. Read is acting Executive Chairman, EBR Systems, a developer of wireless cardiac stimulation therapies, Allay Therapeutics, a developer of opioid-free solutions for treating postoperative pain, and Okogen, an ophthalmic specialty pharmaceutical company. Dr. Read previously served on the Board of Directors of Alexza (NASDAQ: ALXA), AnaptysBio (NASDAQ: ANAB), and CV Therapeutics, Inc. (NASDAQ: CVTX. He is also a founding director of BioVentures for Global Health and has served as a Trustee or Director for a number of other non-profit organizations, including the Santa Fe Institute, the Institute for Systems Biology, the UC Berkeley Foundation and BIO. Earlier in his career, Dr. Read completed internal medicine training at Duke University and the Peter Bent Brigham Hospital and held faculty appointments at the Harvard Medical School and School of Public Health, 131 Table of Contents where his research on decision theory and cost-effectiveness analysis contributed to some of the earliest efforts to demonstrate the economic value of biomedical innovation. Dr. Read has brought his extensive operating experience into roles as a leading investor in the life science space, and currently serves as a Venture Partner at Brandon Capital Partners, Australia and New Zealand’s largest life science investment fund that manages the Medical Research Commercialization Fund. Dr. Read previously served as Managing Director at Alloy Ventures, an early-stage venture capital firm targeting investments in life sciences, information technology and cleantech companies, where Dr. Read continues to serve as a Venture Partner. These roles position Dr. Read to gain early access to key industry trends and deal flow that will accelerate the process of evaluating and selecting an appropriate target for our shareholders. Dr. Read holds a Bachelor of Science from Rice University and an M.D. from the University of Texas Health Science Center at San Antonio. We believe that Dr. Read is qualified to serve on our board of directors and as our co-Chief Executive Officer due to his extensive executive and board experience in the life sciences industry. Louis G. Lange, M.D., Ph.D., one of our Director nominees, has a long and distinguished career as a leading entrepreneur, investor and academic leader in the biotechnology sector, and has been at the forefront of the development of the biotechnology industry over the last three decades. Dr. Lange founded CV Therapeutics (“CVT”), a biotechnology company focused on cardiovascular diseases, in 1992 and served as Chairman, Chief Executive Officer and Chief Scientific Officer. Dr. Lange led the initial public offering of CVT in 1996 after $50 million in venture investments and oversaw the commercial success of CVT, spearheading the growth of Ranexa® and Lexiscan®, two drugs with combined sales in excess of $1.5 billion dollars. Dr. Lange led the sale of CV Therapeutics to Gilead Sciences (NASDAQ: GILD) in 2009 for $1.4 billion dollars, and stayed on as a Senior Advisor reporting to the Chief Executive Officer of Gilead Sciences until 2019. After successfully selling CVT, Dr. Lange founded and sold two additional biotech companies. In 2017, GE Healthcare acquired Rapidscan Pharma Solutions (“RPS”), a developer of a biopharmaceutical stress agent used in the diagnosis of cardiovascular disease. In 2015, Audentes Therapeutics acquired gene therapy products developer Cardiogen Sciences; Dr. Lange stayed on as lead Director up to the sale of Audentes Therapeutics to Astellas Pharma (TYO:4503) in 2020 for $3.1 billion. Currently, Dr. Lange is a Partner at Asset Management Ventures (“AMV”), an early-stage venture capital firm focused on investments in the digital health, technology, and life sciences sectors, sitting at the forefront of key innovation trends and deal flow within the biotechnology space. Dr. Lange has led over 12 investments across all areas of biotechnology companies. In addition to Dr. Lange’s operational and investing experience, Dr. Lange spent 22 years in academic medicine at Harvard and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital at Washington University School of Medicine from 1985-1992 and was one of the first academicians in molecular cardiology. Currently, Dr. Lange serves as a member of the Board of Trustees at the University of Rochester, a role he has held since 1998. As Chair of the Health Affairs committee that oversees all of the medical operations for five years, Dr. Lange has been part of the leadership team for strategic re-invigoration of the medical center with construction of two research buildings and recruitment of over 100 faculty members. Dr. Lange has also led the most respected industry and trade associations in the biotechnology sector. From 1999 to 2009, Dr. Lange served on the Board of Directors of Biotechnology Innovation Organization (the trade organization of biotech companies) leading the largest committee of member companies for two years Dr. Lange has been on numerous other public and private Boards in both the non-profit and for-profit arena, including the 132 Table of Contents Institute of Systems Biology (“ISB”), a nonprofit biomedical research organization co-founded by industry stalwart Dr. Leroy (“Lee”) Hood, and the UCSF Gladstone Institute, an independent, nonprofit life science research organization located in the epicenter of biomedical and technological innovation in the San Francisco Bay Area. Dr. Lange will leverage his extensive operating and academic experience and industry networks to work alongside the management team in identifying high-potential therapeutic areas and treatment approaches, as well as sourcing, evaluating and negotiating with potential targets. Dr. Lange has a Bachelor’s degree from the University of Rochester, an M.D. from Harvard University and a Ph.D. in Biological Chemistry, also from Harvard University. We believe that Dr. Lange is qualified to serve on our board of directors due to his extensive entrepreneurial, investment and academic experience in the life sciences industry. Stephen Sherwin, M.D., one of our Director nominees, is a medical oncologist who has spent over 35 years in the biotechnology industry, helping to create and manage companies that discover and develop new treatments for patients with cancer. During his career as a C-level executive, Dr. Sherwin co-founded and served as CEO and/or chairman of industry-leading biotechnology companies that generated over $2.0 billion in shareholder value. From 1990 to 2009, Dr. Sherwin served as the Chief Executive Officer of Cell Genesys, Inc., a cancer immunotherapy company, and was its Chairman from 1994 until the company’s merger in 2009 with BioSante Pharmaceuticals, Inc. (now ANI Pharmaceuticals, Inc.). In addition, Dr. Sherwin co-founded and served as chairman of Abgenix, Inc., an antibody company that was acquired by Amgen 2006 and co-founded and served as Chairman of Ceregene, Inc., a gene therapy company acquired by Sangamo Biosciences in 2013. Prior to Cell Genesys, Dr. Sherwin served as Vice President of Clinical Research at Genentech and was the first medical doctor hired by the company. In addition to his corporate experience, Dr. Sherwin previously served on the board of directors of the Biotechnology Innovation Organization from 2001 to 2014 and as its chairman from 2009 to 2011. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. Dr. Sherwin is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. In addition, Dr. Sherwin currently serves as a Venture Partner at Third Rock Ventures, a leading healthcare venture firm, and on the boards of directors of Biogen (NASDAQ: BIIB), a multinational commercial-stage biotechnology company and Neurocrine Biosciences (NASDAQ: NBIX), a commercial-stage biopharmaceutical company focused on neurological and endocrine diseases. Through his prior and current experiences and roles, Dr. Sherwin is uniquely able to lend his expertise on next-generation biotechnology trends to work with the team in sourcing an appropriate target with commercial and therapeutic potential, and to provide operational guidance that will be crucial in helping our target achieve successful commercialization and scale as a public company. Dr. Sherwin received his Bachelor of Arts in Biology at Yale University, and his M.D. at Harvard Medical School. We believe that Dr. Sherwin is qualified to serve on our board of directors due to his extensive executive, venture and academic experience in the life sciences industry. Jonathan Rigby, one of our Director Nominees, brings over 30 years of experience leading private and publicly traded biotechnology and pharmaceutical companies in the US, UK, and Israel, and is uniquely positioned to successfully prepare a high-potential target for a successful next phase in the public markets. Mr. Rigby is currently President, Group Chief Executive Officer and Board Member at REVOLO Biotherapeutics (formerly Immune Regulation Ltd and Inc.), a US and UK based clinical stage biotech company developing novel, first-in-class, drug therapies for autoimmune and allergic diseases. From 2011 to 2018, Mr. Rigby served as President and Chief Executive Officer of SteadyMed (NASDAQ: STDY), a US and Israel based company, and led its successful IPO and subsequent public to public company sale to United Therapeutics 133 Table of Contents (NASDAQ: UTHR); he continued to lead the successful integration of the company until November 2019. Mr. Rigby brings extensive experience leading several other private biotechnology companies to the public markets including Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company focused on the development of drug delivery enabled pharmaceuticals, where he was a member of the Board of Directors, Chairman of the Nominating and Governance Committee and member of the IPO pricing committee from 2016-2019. In 2006 Mr. Rigby conceived and co-founded Zogenix Inc. (NASDAQ: ZGNX), that is developing and commercializing transformative therapies for rare diseases, with a successful initial public offering in 2010. Earlier in his career, Mr. Rigby held various commercial roles at Merck and Bristol Myers Squibb. Mr. Rigby also currently serves on the Board of Directors at ImmunoMolecular Therapeutics, Inc., a biotechnology company developing medicines for autoimmune diseases, and was previously Chairman of the Board at Collplant Biotechnologies (NASDAQ: CLGN), a regenerative medicine company. As a seasoned international Chief Executive Officer and Board member, Mr. Rigby will be instrumental in bringing his experience to guide an early-stage biopharmaceutical company through successful commercialization at scale. Mr. Rigby has a Bachelor of Science Degree, with Honors, in Biological Sciences from Sheffield University, UK, and an MBA from Portsmouth University, UK. We believe that Mr. Rigby is qualified to serve on our board of directors due to his extensive operational and board experience in the life sciences industry. Glen Giovannetti, one of our Director nominees, is a retired partner of Ernst & Young LLP (“EY”), where he was instrumental in spearheading the growth of the firm’s life sciences practice. Mr. Giovannetti is a widely recognized industry expert and thought leader, bringing over 36 years of deep life sciences domain knowledge, leadership success, risk and reporting expertise, and board governance credentials. At EY, Mr. Giovannetti served as the Global Biotechnology Leader (2007-2018) and Global Life Sciences Leader (2010-2016) and was intimately involved as lead partner on numerous IPOs and following-on offerings as well as consulting on alliance, merger, and spin-off transactions. Mr. Giovannetti supported client teams from the U.S., across Europe, China, India, Japan, and Brazil. Furthermore, Mr. Giovannetti’s team was responsib

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q 10-Q 2022-11-03
SC 13G SCHEDULE 13G 2022-11-02
8-K 8-K 2022-10-11
10-Q 10-Q 2022-08-10
10-Q 10-Q 2022-05-12
10-K 10-K 2022-03-11
SC 13G/A FORM SC 13G/A 2022-02-14
SC 13G/A FORM SC 13G/A 2022-02-09
SC 13D SC 13D 2021-12-17
8-K FORM 8-K 2021-12-13
SC 13G FORM SC 13G 2021-12-13
SC 13G FORM SC 13G 2021-12-10
8-K FORM 8-K 2021-12-08
4 FORM 4 2021-12-07
424B4 424B4 2021-12-06
EFFECT 2021-12-02
S-1MEF S-1MEF 2021-12-02
3 FORM 3 2021-12-02
3 FORM 3 2021-12-02
3 FORM 3 2021-12-02
3 FORM 3 2021-12-02
3 FORM 3 2021-12-02
3 FORM 3 2021-12-02
3 FORM 3 2021-12-02
3 FORM 3 2021-12-02
CERT 2021-12-02
8-A12B 8-A12B 2021-12-01
CORRESP 2021-11-30
CORRESP 2021-11-30
S-1/A AMENDMENT NO. 1 TO FORM S-1 2021-11-29
S-1/A AMENDMENT NO. 1 TO FORM S-1 2021-11-12
S-1 S-1 2021-07-20
UPLOAD 2021-07-01
DRS 2021-06-22